Literature DB >> 11864954

Potential of rifamides to inhibit TNF-induced NF-kappaB activation.

Ali A Pahlevan1, David J M Wright, Laura Bradley, Clive Smith, Brian M J Foxwell.   

Abstract

Rifamides are important components in the treatment of tuberculosis. However, it is well documented that these drugs can have immunosuppressive activity, a property of these drugs that is particularly relevant to AIDS patients. In this study, we have shown that a number of rifamide analogues have the potential to block tumour necrosis factor (TNF)- or phorbol myristate acetate-induced NF-kappaB activation. As TNF is important in the host defence against tuberculosis, suppression of this activity may provide a potential mechanism of rifamide immunosuppressive activity.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11864954     DOI： 10.1093/jac/49.3.531

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  9 in total

1.  Effect of rifampin on production of inflammatory mediators in HepG2 liver epithelial cells.

Authors:  Yael Yuhas; Eva Berent; Shai Ashkenazi
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Rifampin augments cytokine-induced nitric oxide production in human alveolar epithelial cells.

Authors:  Yael Yuhas; Eva Berent; Hila Ovadiah; Inbar Azoulay; Shai Ashkenazi
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Rifampicin Inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-kappaB DNA-binding Activity in RAW 264.7 Cells.

Authors:  Seong Keun Kim; Young Mi Kim; Chung Eun Yeum; Song-Hyo Jin; Gue Tae Chae; Seong-Beom Lee
Journal:  Korean J Physiol Pharmacol       Date:  2009-12-31       Impact factor: 2.016

4.  Rifampin inhibits prostaglandin E2 production and arachidonic acid release in human alveolar epithelial cells.

Authors:  Yael Yuhas; Inbar Azoulay-Alfaguter; Eva Berent; Shai Ashkenazi
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

5.  Roles of NF-kappaB activation and peroxisome proliferator-activated receptor gamma inhibition in the effect of rifampin on inducible nitric oxide synthase transcription in human lung epithelial cells.

Authors:  Yael Yuhas; Eva Berent; Regev Cohen; Shai Ashkenazi
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

6.  Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain.

Authors:  Xiaohui Wang; Peter M Grace; Michael N Pham; Kui Cheng; Keith A Strand; Christina Smith; Jing Li; Linda R Watkins; Hang Yin
Journal:  FASEB J       Date:  2013-04-08       Impact factor: 5.191

7.  Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors.

Authors:  Rajesh Kumar; Ram A Bumb; Poonam Salotra
Journal:  Immunology       Date:  2010-01-22       Impact factor: 7.397

8.  Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection.

Authors:  Claudia Manca; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Gilla Kaplan; Selvakumar Subbian
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

9.  The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER.

Authors:  Belinda S Hall; Kirsti Hill; Michael McKenna; Joy Ogbechi; Stephen High; Anne E Willis; Rachel E Simmonds
Journal:  PLoS Pathog       Date:  2014-04-03       Impact factor: 6.823
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.